Products
Preparation registered in Ukraine
Lisunets O., Haniukova I.
Efficacy and safety of irbesartan in treatment of patients and invalids as a result of hypertension with very high additional risk
The aim of this study was to investigate antihypertensive efficacy and safety of irbesartan (Irbetan produced by “Kyiv Vitamin Factory”) in treatment of patients with arterial hypertension (AH) with a high risk of cardiovascular complications; explore the effects of treatment on clinical markers of renal and vascular endothelial function. The study demonstrated that long-term use of antihypertensive treatment in hypertensive patients with underlying conditions and high risk of cardiovascular complications, which is based on the use of irbetan at a dose 300 mg/day, has a fairly high level of success in achieving target levels of blood pressure, reduced “load pressure” both in the daytime and at night.
Key words: hypertension, the risk of cardiovascular events, irbesartan, Irbetan.